The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy
The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Abstract
Accumulating data indicate that oxidative stress (OS) plays a major role in the pathogenesis of multiple sclerosis (MS). Reactive oxygen species (ROS), leading to OS, generated in excess primarily by macrophages, have been implicated as mediators of demyelination and axonal damage in both MS and experimental autoimmune encephalomyelitis (EAE), its animal model. ROS cause damage to cardinal cellular components such as lipids, proteins and nucleic acids (e. g., RNA, DNA), resulting in cell death by necrosis or apoptosis. In addition, weakened cellular antioxidant defense systems in the central nervous system (CNS) in MS, and its vulnerability to ROS effects may increase damage. Thus, treatment with antioxidants might theoretically prevent propagation of tissue damage and improve both survival and neurological outcome. Indeed, several experimental studies have been performed to see whether dietary intake of several antioxidants prevents or reduces the progression of EAE. Although a few antioxidants showed some efficacy in these studies, little information is available on the effect of treatments with such compounds in patients with MS. Well-designed clinical studies using antioxidant intake, as well as investigations based on larger cohorts studied over a longer periods of time, are needed in order to assess whether antioxidant intake together with other conventional treatments, might be beneficial in treating MS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative damage and mitochondrial dysfunction are key features of MS pathology [277,278,279,280].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [277]
Citations
Cites
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669 · cited 1×
“In addition, free radicals can activate certain transcription factors, such as nuclear transcription factor-kappa B (NF-κB), which upregulate the expression of many genes involved in EAE and MS, such as tumor necrosis factor-α (TNF-α), nitric oxide synthase (iNOS), intracellular adhesion molecule 1 (ICAM-1) and vascul…”
BackgroundAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532 · cited 10×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundInfluentialA Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242 · cited 1×
“Other novel treatments requiring the evaluation of larger, placebocontrolled trials are estriol, [64] statins [54] and natalizumab, which is an α4 integrin antagonist [51].”
BackgroundWeinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894 · cited 1×
“In addition, immunosuppression therapy with drugs such as azathioprine [82], cyclophosphamide [10], intravenous immune globulin (IVIG) [1] and additional therapies such as Plasmapheresis [79] have also been suggested.”
BackgroundGilgun-Sherki, Y., Melamed, E., & Offen, D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00019-3 · Cited by 838
Self-citationGlutamate excitotoxicity in a model of multiple sclerosis
Pitt, D., Werner, P., & Raine, C. S. (2000) · Nature Medicine · doi:10.1038/71555 · Cited by 744 · cited 2×
“In one of these studies [58],mice acquired EAE after transfer of lymph node cells sensitized to myelin basic protein.”
BackgroundComi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Demyelination: The Role of Reactive Oxygen and Nitrogen Species
Smith, K. J., Kapoor, R., & Felts, P. A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00212.x · Cited by 600 · cited 1×
“Consistent with this possibility, the neurological deficit resulting from EAE has generally been reduced by trial therapies to diminish the concentration of ROS [66].”
BackgroundHooper, D. C., Spitsin, S., Kean, R. B., Champion, J. M., Dickson, G. M., Chaudhry, I., & Koprowski, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.675 · Cited by 569 · cited 1×
“[31, 32] demonstrated that the inhibition of iNOS, or scavenging of NO· or peroxynitrite by uric acid, inhibited neurological deficits in mice with EAE [31, 32], while withdrawal of iNOS inhibitor resulted in the appearance of neurological signs within 24 hours [31, 32].”
BackgroundInduction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains
Bö, L., Dawson, T. M., Wesselingh, S., Möurk, S., Choi, S., Kong, P. A., Hanley, D., & Trapp, B. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360515 · Cited by 567 · cited 1×
“Oxygen and nitrogen free radicals generated by macrophages have been implicated as mediators of demyelination and axonal injury in both EAE and MS [5,38,74].”
BackgroundMcdonald, J. W., Althomsons, S. P., Hyrc, K. L., Choi, D. W., & Goldberg, M. P. (1998) · Nature Medicine · doi:10.1038/nm0398-291 · Cited by 544 · cited 1×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48 ], which have higher permeability to Ca2 + [7].”
BackgroundT cell gelatinases mediate basement membrane transmigration in vitro.
Leppert, D., Waubant, E., Galardy, R., Bunnett, N. W., & Hauser, S. L. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.9.4379 · Cited by 492 · cited 10×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundInfluentialWerner, P., Pitt, D., & Raine, C. S. (2001) · Annals of Neurology · doi:10.1002/ana.1077 · Cited by 486 · cited 1×
“There is also evidence in MS of an increase in cerebrospinal fluid (CSF) levels of glutamate in association with the severity and course of the disease [69, 3] and that glutamate production by macrophages may underlie axonal damage and oligodendrocytes death in MS lesions [ 80 ].”
BackgroundAxonal pathology in multiple sclerosis: relationship to neurologic disability
Trapp, B. D., Ransohoff, R., & Rudick, R. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199906000-00008 · Cited by 475 · cited 10×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundInfluentialHISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSE
Jersild, C., Hansen, G., Svejgaard, A., Fog, T., Thomsen, M., & Dupont, B. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90970-7 · Cited by 469
Autoimmune encephalomyelitis ameliorated by AMPA antagonists
Smith, T., Groom, A., Zhu, B., & Turski, L. (2000) · Nature Medicine · doi:10.1038/71548 · Cited by 467 · cited 3×
“Another study [67], used the Lewis rat model of acute EAE, in which little demyelination occurs, and also the chronic EAE model.”
BackgroundMethodGlutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes
Volterra, A., Trotti, D., Tromba, C., Floridi, S., & Racagni, G. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-05-02924.1994 · Cited by 461 · cited 1×
“Oxidative stress might also contribute to the increase in glutamate concentration in the extra-cellular space by reducing the efficiency of glutamate transporters [77].”
BackgroundTreatment of multiple sclerosis with the pregnancy hormone estriol
Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C. J., & Voskuhl, R. R. (2002) · Annals of Neurology · doi:10.1002/ana.10301 · Cited by 435 · cited 1×
“Other novel treatments requiring the evaluation of larger, placebocontrolled trials are estriol, [64] statins [54] and natalizumab, which is an α4 integrin antagonist [51].”
BackgroundA population‐based study of multiple sclerosis in twins: Update
Sadovnick, A. D., Armstrong, H., Rice, G. P. A., Bulman, D., Hashimoto, L., Party, D. W., Hashimoto, S. A., Warren, S., Hader, W., Murrary, T. J., et al. (1993) · Annals of Neurology · doi:10.1002/ana.410330309 · Cited by 422
Cross, A. H., Misko, T. P., Lin, R. F., Hickey, W. F., Trotter, J. L., & Tilton, R. G. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117282 · Cited by 384 · cited 1×
“Several investigators have shown that inhibition of the inducible/inflammatory form of iNOS, as well as the use of anti-sense knockdown of iNOS, suppress EAE in mice and rats [6, 14, 18, 84].”
BackgroundGlutamate receptor-mediated toxicity in optic nerve oligodendrocytes
Matute, C., Sánchez-Gómez, M. V., Martínez-Millán, L., & Miledi, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8830 · Cited by 352 · cited 1×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundHooper, D. C., Bagasra, O., Marini, J. C., Zborek, A., Ohnishi, S. T., Kean, R., Champion, J. M., Sarker, A. B., Bobroski, L., Farber, J. L., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2528 · Cited by 334 · cited 1×
“[31, 32] demonstrated that the inhibition of iNOS, or scavenging of NO· or peroxynitrite by uric acid, inhibited neurological deficits in mice with EAE [31, 32], while withdrawal of iNOS inhibitor resulted in the appearance of neurological signs within 24 hours [31, 32].”
BackgroundIntravenous immunoglobulin treatment in multiple sclerosis Effect on relapses
Achiron, A., Gabbay, U., Gilad, R., Hassin-Baer, S., Barak, Y., Gornish, M., Elizur, A., Goldhammer, Y., & Sarova-Pinhas, I. (1998) · Neurology · doi:10.1212/wnl.50.2.398 · Cited by 256 · cited 1×
“In addition, immunosuppression therapy with drugs such as azathioprine [82], cyclophosphamide [10], intravenous immune globulin (IVIG) [1] and additional therapies such as Plasmapheresis [79] have also been suggested.”
BackgroundComabella, M., Balashov, K., Issazadeh, S., Smith, D., Weiner, H. L., & Khoury, S. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3125 · Cited by 221 · cited 1×
“In addition, immunosuppression therapy with drugs such as azathioprine [82], cyclophosphamide [ 10 ], intravenous immune globulin (IVIG) [1] and additional therapies such as Plasmapheresis [79] have also been suggested.”
BackgroundOverview of azathioprine treatment in multiple sclerosis
Yudkin, P. L., Ellison, G. W., Ghezzi, A., Goodkin, D. E., Hughes, R. A. C., McPherson, K., Mertin, J., & Milanese, C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91909-e · Cited by 219 · cited 1×
“In addition, immunosuppression therapy with drugs such as azathioprine [82], cyclophosphamide [10], intravenous immune globulin (IVIG) [1] and additional therapies such as Plasmapheresis [79] have also been suggested.”
BackgroundStatins as immunomodulators: Comparison with interferon-β1b in MS
Neuhaus, O., Strasser-Fuchs, S., Fazekas, F., Kieseier, B. C., Niederwieser, G., Hartung, H. P., & Archelos, J. J. (2002) · Neurology · doi:10.1212/wnl.59.7.990 · Cited by 215
Extracellular Matrix‐Degrading Proteinases in the Nervous System
Romanic, A. M., & Madri, J. A. (1994) · Brain Pathology · doi:10.1111/j.1750-3639.1994.tb00825.x · Cited by 207 · cited 10×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundInfluentialReactive oxygen species are required for the phagocytosis of myelin by macrophages
van der Goes, A., Brouwer, J., Hoekstra, K., Roos, D., van den Berg, T. K., & Dijkstra, C. D. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00175-1 · Cited by 181 · cited 1×
“Oxygen and nitrogen free radicals generated by macrophages have been implicated as mediators of demyelination and axonal injury in both EAE and MS [5,38,74].”
BackgroundDe Stefano, N., Narayanan, S., Matthews, P. M., Francis, G. S., Antel, J. P., & Arnold, D. L. (1999) · Brain · doi:10.1093/brain/122.10.1933 · Cited by 181 · cited 10×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundInfluentialNeurotransmitters in cerebrospinal fluid reflect pathological activity
STOVER, J. F., PLEINES, U. E., MORGANTI‐KOSSMANN, M. C., KOSSMANN, T., LOWITZSCH, K., & KEMPSKI, O. S. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.2250774.x · Cited by 170 · cited 1×
“There is also evidence in MS of an increase in cerebrospinal fluid (CSF) levels of glutamate in association with the severity and course of the disease [69, 3] and that glutamate production by macrophages may underlie axonal damage and oligodendrocytes death in MS lesions [80].”
BackgroundRuuls, S. R., Bauer, J., Sontrop, K., Huitinga, I., Hart, B. A. ‘., & Dijkstra, C. D. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00154-g · Cited by 162 · cited 1×
“Another investigation showed that intra-peritoneal administration of catalase before the onset of neurological deficit delayed the onset of EAE and reduced its severity and duration [61].”
BackgroundStinissen, P., Raus, J., & Zhang, J. (1997) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v17.i1.20 · Cited by 158 · cited 1×
“The etiology of MS has not yet been fully elucidated, but it is believed that immunological mechanisms are the most important in disease initiation and progression [68].”
BackgroundWeinshenker, B. G., Santrach, P., Bissonet, A. S., McDonnell, S. K., Schaid, D., Moore, S. B., & Rodriguez, M. (1998) · Neurology · doi:10.1212/wnl.51.3.742 · Cited by 152
Schrijver, H. M., Crusius, J. B. A., Uitdehaag, B. M. J., García-González, M. A., Kostense, P. J., Polman, C. H., & Peña, A. S. (1999) · Neurology · doi:10.1212/wnl.52.3.595 · Cited by 150
Zhao, W., Tilton, R. G., Corbett, J. A., McDaniel, M. L., Misko, T. P., Williamson, J. R., Cross, A. H., & Hickey, W. F. (1996) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00158-1 · Cited by 147 · cited 1×
“Several investigators have shown that inhibition of the inducible/inflammatory form of iNOS, as well as the use of anti-sense knockdown of iNOS, suppress EAE in mice and rats [6, 14, 18, 84].”
BackgroundMarracci, G., Jones, R. E., McKeon, G. P., & BOURDETTE, D. N. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00269-2 · Cited by 144 · cited 1×
“The authors’ conclusion was that alpha lipoic acid suppressed EAE probably by inhibiting T cell trafficking into the spinal cord, perhaps by the inhibition of MMP9 activity [45].”
BackgroundA meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations
Miller, D. M., Weinstock‐Guttman, B., Béthoux, F., Lee, J.-C., Beck, G. J., Block, V., Durelli, L., LaMantia, L., Barnes, D., Sellebjerg, F. T., et al. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600408 · Cited by 130 · cited 1×
“The therapy of choice for acute relapses in MS is based upon high dose, short-term pulse therapy with prednisolone or methyl prednisolone [50] and immunomodulatory treatments such as interferon beta-1a [9] and –1b [26], glatiramer acetate (copaxone®) [11], and mitoxantrone [15].”
BackgroundDing, M., Zhang, M., Wong, J. L., Rogers, N. E., Ignarro, L. J., & Voskuhl, R. R. (1998) · PubMed · Cited by 122
(1998) · Progress in Brain Research · doi:10.1016/s0079-6123(08)63196-9 · Cited by 120 · cited 1×
“Other ROS includes hydroxyl radical (OH·), hydrogen peroxide (H2O2), peroxynitrite (ONOO) and nitric oxide (NO·) the last named was shown to be produced by reactive astrocytes via cytokine-mediated induction of nitric oxide synthase [16].”
BackgroundAntioxidants, Redox-Regulated Transcription Factors, and Inflammation
Winyard, P. G., & Blake, D. R. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60993-x · Cited by 118 · cited 1×
“In addition, free radicals can activate certain transcription factors, such as nuclear transcription factor-kappa B (NF-κB), which upregulate the expression of many genes involved in EAE and MS, such as tumor necrosis factor-α (TNF-α), nitric oxide synthase (iNOS), intracellular adhesion molecule 1 (ICAM-1) and vascul…”
BackgroundCalcium permeability of glutamate-gated channels in the central nervous system
Burnashev, N. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80113-9 · Cited by 118 · cited 1×
“It was found that oligodendrocytes, the myelin-producing cell of the CNS, are highly vulnerable to glutamate excitotoxicity, mainly via the AMPA/kainate receptors [46, 48], which have higher permeability to Ca2 + [7].”
BackgroundNovel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders
Hall, E. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320724 · Cited by 117 · cited 1×
“Hall and colleagues [28] found that the antioxidant tirilazade mesylate, a member of the lazaroids family which were shown to scavenge lipid peroxyl radicals and inhibit iron-dependent lipid peroxidation, was effective in reducing the incidence and severity of actively-induced EAE.”
BackgroundAnti-MOG and anti-MBP antibody subclasses in multiple sclerosis
Egg, R., Reindl, M., Deisenhammer, F., Linington, C., & Berger, T. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700503 · Cited by 116 · cited 1×
“Indeed, autoantibodies against MBP and MOG have been found in MS patients [20].”
BackgroundMerrill, J. E., & Murphy, S. P. (1997) · Brain Behavior and Immunity · doi:10.1006/brbi.1997.0496 · Cited by 110 · cited 1×
“Also, redox reactions are involved in the activity of matrix metalloproteinases (MMP), which are important to T cell trafficking into the CNS [41, 49 , 60].”
BackgroundAxonal degeneration in the pathogenesis of multiple sclerosis
Silber, E., & Sharief, M. K. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00178-1 · Cited by 102
Association of the APOE epsilon 4 allele with disease activity in multiple sclerosis
Evangelou, N., Jackson, M., Beeson, D., & Palace, J. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.2.203 · Cited by 102 · cited 1×
“Genetic factors such as interleukin-1 beta [63], interleukin-1 receptor [63], immunoglobulin Fc receptor genes [52], and apolipoprotein E (APO-E) gene [ 21 ] have been suggested as having a substantial effect on susceptibility to MS [62].”
BackgroundCerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis
Greco, A., Minghetti, L., Sette, G., Fieschi, C., & Levi, G. (1999) · Neurology · doi:10.1212/wnl.53.8.1876 · Cited by 98 · cited 1×
“Examination of cerebrospinal fluid showed significantly higher concentration of isoprostanes [27] and increase of malondialdehyde (MDA) and glutathione reductase activity and decrease of glutathione peroxidase activity [8].”
BackgroundLangemann, H., Kabiersch, A., & Newcombe, J. (2008) · European Neurology · doi:10.1159/000116835 · Cited by 91 · cited 1×
“Moreover, direct examination of MS plaques has revealed increased free radical activity, along with decreased levels of important antioxidants such as glutathione, alpha-tocopherol and uric acid [ 39 ].”
BackgroundThe role of reactive oxygen species in the pathogenesis of multiple sclerosis
LeVine, S. M. (1992) · Medical Hypotheses · doi:10.1016/0306-9877(92)90121-r · Cited by 87 · cited 1×
“Numerous studies of patients with MS have shown increased free radical activity, and/or deficiencies in important antioxidant enzymes compared with healthy controls [42].”
BackgroundMalfroy, B., Doctrow, S. R., Orr, P. L., Tocco, G., Fedoseyeva, E. V., & Bénichou, G. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1091 · Cited by 86 · cited 2×
“Moreover, the authors showed that post treatment with Euk-8, 4 days after EAE induction, also resulted in a significant amelioration of EAE [44].”
BackgroundCowden, W. B., Cullen, F. A., Staykova, M. A., & Willenborg, D. O. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00040-x · Cited by 79
Naidoo, R., & Knapp, M. L. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.12.2449 · Cited by 77 · cited 1×
“Earlier studies found evidence of lipid peroxidation in the CSF [33], and in the plasma of patients with MS [53].”
BackgroundNonenzymatic antioxidants of blood in multiple sclerosis
Karg, E., Klivènyi, P., Németh, I., Bencsik, K., Pintér, S., & Vécsei, L. (1999) · Journal of Neurology · doi:10.1007/s004150050399 · Cited by 72 · cited 1×
“[37] found a 38 % increase in lipid peroxidation, significantly elevated levels of oxidized glutathione, and a reduction in the plasma vitamin E: lipid ratio during the active phase of MS.”
BackgroundCalabrese, V., Raffaele, R., Cosentino, E. R., & Rizza, V. (1994) · PubMed · Cited by 68
Changes in neurotransmitters in multiple sclerosis
Vp, B., Завалишин, И. А., Аскарова, Л. Ш., Shavratskii, V. K., & Demina, E. G. (1998) · Neuroscience and Behavioral Physiology · doi:10.1007/bf02464784 · Cited by 68 · cited 1×
“There is also evidence in MS of an increase in cerebrospinal fluid (CSF) levels of glutamate in association with the severity and course of the disease [69, 3] and that glutamate production by macrophages may underlie axonal damage and oligodendrocytes death in MS lesions [80].”
BackgroundVladimirova, O. V., Lu, F. M., Shawver, L., & Kálmán, B. (1999) · Inflammation Research · doi:10.1007/s000110050480 · Cited by 58
Lehmann, D., Karussis, D. M., Misrachi-Koll, R., Shezen, E., Ovadia, H., & Abramsky, O. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90212-7 · Cited by 51 · cited 1×
“The protection was associated with enhancement of the specific lymphocyte proliferative response to the immunizing antigens (spinal cord homogenate) at early stages, post encephalitogenic injection [40].”
BackgroundOxidative stress in patients with multiple sclerosis.
Syburra, C., & Passi, S. (1999) · PubMed · Cited by 51
Eating Patterns in Women with Multiple Sclerosis
Timmerman, G. M., & Stuifbergin, A. K. (1999) · Journal of Neuroscience Nursing · doi:10.1097/01376517-199906000-00004 · Cited by 33 · cited 1×
“Only two studies of mild to severely disabled subjects have been performed to date, suggesting that the degree of MS disability did not correlate significantly with intake of specific nutrients [30, 71].”
BackgroundJensen, G. E., & Clausen, J. (1986) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1986.tb02800.x · Cited by 28 · cited 1×
“[35] showed that supplementation with antioxidants (6.”
Food intake in multiple sclerosis.
Dc, H., Ma, P., Ke, S., Drury, P., & Ma, C. (1984) · PubMed · Cited by 27
On the causes of multiple sclerosis
Hutter, C. D. D. (1993) · Medical Hypotheses · doi:10.1016/0306-9877(93)90052-r · Cited by 25 · cited 2×
“Following the encouraging findings in the EAE models, many authors have suggested that dietary antioxidant intake i. e., vitamin E or selenium may help to inhibit disease progression [12, 34 , 70].”
Background[Superoxide dismutase (SOD-1) activity in erythrocytes of patients with multiple sclerosis].
Zagórski, T., Dudek, I., Berkan, L., Mazurek, M., Kȩdziora, J., & Chmielewski, H. (1991) · PubMed · Cited by 17
Multiple sclerosis: an immune legacy?
Cooper, R. L. T. (1997) · Medical Hypotheses · doi:10.1016/s0306-9877(97)90196-1 · Cited by 13 · cited 2×
“Others have suggested that excess ROS can stimulate heightened T-cell activity via an arachidonic acid cascade, or produce direct/indirect damage to brain-blood barrier (BBB) or myelin [12].”
BackgroundDudek, I., Zagórski, T., Liskiewicz, J., Kȩdziora, J., & Chmielewski, H. (1992) · PubMed · Cited by 9
Cited by
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
“Upper abdominal pain‡ 17 (5) 36 (10) 33 (10) 4 (1)”
Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease
Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130
Huang, Z., Rose, A. H., & Hoffmann, P. R. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4145 · Cited by 908
“ROS have also been suggested to be involved in the pathogenesis of multiple sclerosis (86) and type-1 diabetes (40).”
BackgroundOxidative Stress and Neurotoxicity
Sayre, L. M., Perry, G., & Smith, M. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 867
Metadata
- Authors
- Offen, D., Gilgun-Sherki, Y., & Melamed, E.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Offen, Daniel
- ORCID
- Offen, Daniel
- Venue
- Journal of Neurology
- Published
- 2004-03-01
- Volume
- 251
- Issue
- 3
- Pages
- 261-268
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2023725391
- Cited by
- 638
- References
- 67
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 29 · 2023: 25 · 2022: 17 · 2021: 31 · 2020: 29 · 2019: 47 · 2018: 45 · 2017: 44 · 2016: 36 · 2015: 35 · 2014: 46 · 2013: 33 · 2012: 28
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Health Sciences › Medicine › Physiology (medical) › Exercise and Physiological Responses
- Keywords
- oxidative stress, multiple sclerosis, reactive oxygen species, antioxidant therapy, experimental autoimmune encephalomyelitis, demyelination, axonal injury, macrophages, apoptosis, dietary antioxidants, central nervous system, pathogenesis
- MeSH terms
- Animals, Antioxidants, Clinical Trials as Topic, Free Radicals, Humans, Multiple Sclerosis, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.